INTRODUCTION AND OBJECTIVES: PD-1 blockade have been reported as a promising therapeutic strategy against several solid tumors. However, the unresponsiveness and adverse side effects diminish the therapeutic effects of PD-1 blockade immunotherapy. Nitroxoline, an FDA-approved treatment for urinary tract infections, exhibits anticancer activities by the activation of cell apoptosis, cell cycle arrest, and suppression of angiogenesis. The purpose of this study was to explore whether combining nitroxoline with PD-1 blockade can further improve existing immunotherapy in the mouse prostate cancer orthotopic tumor model. METHODS: We performed XTT and colony formation assays to evaluate the effects of nitroxoline on RM9-LUC-PIRES-KLK3 cell, a mouse prostate cancer cell line, viability and proliferation. The cell cycle distribution were analysed by flow cytometry. And then we investigated the effects of nitroxoline on the PI3K/AKT pathway using western blot analysis. In vivo, stable luciferase-transfected RM9-Luc-pIRES-KLK cells in C57BL/6 mice by orthotopic implantion were imaged with the IVIS imaging system over time. Serum PSA levels in mouse peripheral blood were measured with human PSA ELISA kit. In addition, the expression of CD31 and Ki-67 was evaluated by immune-histochemistry staining. Finally, the percentages of CD44þCD62LþCD8þ memory and TNFaþCD3þCD8þ T cells and myeloid-derived suppressor cells (MDSCs) in peripheral blood cells were quantified by FACS analysis.
RESULTS: We found that nitroxoline markedly inhibited RM9-LUC-PIRES-KLK3 cell proliferation and colony formation in vitro. Nitroxoline also significantly caused cell cycle arrest at S phase. Additionally, we found that nitroxoline treatment reduced protein levels of phospho-AktSer473 and phospho-AktSer308 in a dose-dependent manner. Moreover, their expression further decreased in RM9-LUC-PIRES-KLK3 cells treated with a PI3K inhibitor LY294002, suggesting that the effect of nitroxoline may be mediated by modulation the PI3K/ Akt pathway. Furthermore, examination in the murine RM9-LUC-PIRES-KLK3 prostate cancer orthotopic tumor model revealed that combining nitroxoline with an PD-1 blockade enhanced the anti-tumor efficacy compared to those of nitroxoline or PD-1 blockade monotherapy. These effects included the reduction of tumor weights, luciferinstained images, and serum tumor marker PSA levels, which was accompanied by the infiltration of TNFaþCD3þCD8þ T cells and memory T cells and reduced accumulation of MDSCs.
CONCLUSIONS 
MP65-01 4N1K-PEPTIDE DERIVED FROM THROMBOSPONIDN-2 IS ASSOCIATED WITH MALIGNANT AGGRESSIVENESS AND PROGNOSIS IN BLADDER CANCER
Yasuyoshi Miyata, Tsutomu Yuno*, Kyohei Araki, Yuichiro Nakamura, Takuji Yasuda, Yuji Sagara, Tomohiro Matsuo, Kojiro Ohba, Hideki Sakai, Nagasaki, Japan INTRODUCTION AND OBJECTIVES: Thrombospondins (TSPs) play various important roles under pathological conditions. TSP-1 is well-known and recognised as strong angiogenesis inhibitors in various types of cancers. The 4N1K-peptide (KRFYVVMWKK) is reported to be derived from TSP-1 and TSP-2, and its expression was significantly associated with tumor progression and survival in several cancers. In contrast to TSP-1, pathological significance of TSP-2 and 4N1K-peptide in bladder cancer (BC) are not clear. The main aim is to clarify the pathological roles of TSP-2 and 4N1K-peptide in BC because fewer studies have evaluated them in these patients.
METHODS: We immunohistochemically examined 206 BC tissues for TSP-2, and 4N1K-peptide expressions. Their independent contributions to cancer cell proliferation were measured by anti-Ki-67 antibody; apoptosis was measured by anti-cleaved caspase-3 antibody; angiogenesis was measured by anti-CD34 antibody, and MMP-9 immunoreactivity was also examined in these tissues.
RESULTS: TSP-2 expression was negatively associated with T stage (P < 0.001), metastasis (P ¼ 0.021), and grade (P ¼ 0.018). Similar negative relationships were also detected with respect to 4N1K-peptide expression (P < 0.001, 0.025, and 0.002, respectively). TSP-2 expression was negatively associated with cell proliferation (P ¼ 0.005) and MMP-9 expression (P < 0.001), whereas 4N1K-peptide was significantly associated with apoptosis (P < 0.001), angiogenesis (P ¼ 0.024), and MMP-9 expression (P ¼ 0.005). Subsequently, when the independent role of TSP-2 or 4N1K-peptide was investigated by using a multivariate analysis model, including all pathological features, TSP-2 expression was significantly associated with MMP-9 expression (odds ratio ¼ 0.33, 95% confidential interval, CI ¼ 0.17e0.64, P ¼ 0.001). A similar independent correlation was detected between 4N1K-peptide expression and MVD (odds ratio ¼ 0.52, 95% CI ¼ 0.29e0.95, P ¼ 0.033). In survival analyses, multivariate analyses e858 THE JOURNAL OF UROLOGY â Vol. 199, No. 4S, Supplement, Sunday, May 20, 2018 
